Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Zevra Therapeutics Inc ZVRA

Healthcare
Zevra Therapeutics, Inc. is a rare disease company science, data, and patients need to create transformational therapies for diseases with limited or no treatment options. The Company has a diverse portfolio of products and product candidates, which includes a combination of both a clinical stage pipeline and commercial stage assets. Its pipeline includes arimoclomol, an orally delivered... see more

Recent & Breaking News (NDAQ:ZVRA)

KemPharm Supports Niemann-Pick Awareness Month During October and Global Niemann-Pick Awareness Day on October 19th

GlobeNewswire October 4, 2022

KemPharm Announces Positive Topline Data from Phase 1 Clinical Trial Evaluating Cardiovascular Safety of Serdexmethylphenidate (SDX)

GlobeNewswire September 28, 2022

KemPharm to Present at the H.C. Wainwright 24th Annual Global Investment Conference

GlobeNewswire September 1, 2022

KemPharm Reports Second Quarter 2022 Financial Results and Corporate Updates

GlobeNewswire August 11, 2022

KemPharm Appoints Nichol Ochsner as Vice President, Investor Relations and Corporate Communications

GlobeNewswire August 9, 2022

KemPharm to Report Second Quarter 2022 Financial Results

GlobeNewswire August 4, 2022

KemPharm to Present at the Canaccord Genuity 42nd Annual Growth Conference

GlobeNewswire August 2, 2022

KemPharm to Participate in the 2022 Joint NNPDF-INPDA Conference and Meeting

GlobeNewswire July 26, 2022

KemPharm Announces Research Affirming Serdexmethylphenidate's Lower Potential for Abuse Featured in Peer-Reviewed Publication, Current Medical Research & Opinion

GlobeNewswire June 1, 2022

KemPharm Announces Strategic Acquisition of Arimoclomol from Orphazyme, Expanding its Rare CNS Diseases Pipeline

GlobeNewswire May 15, 2022

KemPharm Reports First Quarter 2022 Financial Results and Corporate Updates

GlobeNewswire May 12, 2022

KemPharm to Present at Multiple Upcoming Investor Conferences

GlobeNewswire May 11, 2022

KemPharm Announces Submission of Investigational New Drug Application for Phase 2 Trial of KP1077 in Idiopathic Hypersomnia (IH)

GlobeNewswire May 5, 2022

KemPharm to Report First Quarter 2022 Financial Results

GlobeNewswire May 4, 2022

KemPharm Doses First Subject in Phase 1 Clinical Trial Evaluating Cardiovascular Safety of Serdexmethylphenidate (SDX)

GlobeNewswire April 19, 2022

KemPharm Reports Fourth Quarter and Fiscal Year 2021 Financial Results and Corporate Updates

GlobeNewswire March 30, 2022

KemPharm to Participate in Maxim's 2022 Virtual Growth Conference

GlobeNewswire March 24, 2022

KemPharm Announces Full Data Set from Higher-Dose Serdexmethylphenidate (SDX) Phase 1 Clinical Trial

GlobeNewswire March 21, 2022

KemPharm Earns $1.975 Million Fee from Corium Following FDA Approval of the Corium Product ADLARITY® (donepezil transdermal system)

GlobeNewswire March 16, 2022

KemPharm to Report Fourth Quarter and Full-Year 2021 Results

GlobeNewswire March 10, 2022